MARIPOSA

Key outcome parameters

Intervention

amivantamab, lazertinib, chemotherapy

Key inclusion criteria

Inclusion criteria:

• articipant must have histologically or cytologically confirmed, locally advanced or metastatic, non-squamous NSCLC, characterized at or after the time of locally advanced metastatic disease diagnosis by either EGFR Exon 19del or Exon 21 L858R mutation
• Participant must have progressed on or after osimertinib monotherapy as the most recent line of treatment. Osimertinib must have been administered as either the first-line treatment for locally advanced or metastatic disease or in the second-line setting after prior treatment with first- or second-generation EGFR TKI.
• Participant must have at least 1 measurable lesion, according to RECIST v1.1
• A participant with definitively, locally treated brain metastases must be clinically stable and asymptomatic, with or without low-dose corticosteroid treatment (≤10 mg prednisone or equivalent), for at least 14 days prior to randomization.
• ECOG 0-1

Key exclusion criteria

Exclusion criteria:

• Participant received prior systemic anticancer therapy in the locally advanced or metastatic setting, or in the adjuvant setting, for the same nonsquamous NSCLC intended for treatment now
• Participant received radiotherapy for palliative treatment of NSCLC less than 14 days prior to randomization
• Participant has active brain metastases not definitively treated with local therapy
• Participant has known small cell transformation
• Participant has uncontrolled tumor-related pain
• Participant has a medical history of ILD, including drug-induced ILD or radiation pneumonitis